Johnson & Johnson (JNJ) shares: returns by year and worst falls
Johnson & Johnson · Health Care · number 17 in the S&P 500 by weight
Johnson & Johnson is a health-care company founded in 1886. After separating its consumer products business in 2023 it has two parts: medicines and medical devices.
Johnson & Johnson in numbers: returns and worst fall since 1970
$10,000 put into Johnson & Johnson in Jan 1970 and left alone was worth about $7,581,000 in Nov 2026. That is 12.4% a year over 57 years (JNJ shares, total return).
The worst fall in that time was −50.7%, from the high in Nov 1972 to the low in Apr 1977. It was back at its old high in May 1981.
The best calendar year was 1971 (+73.7%), the worst was 1974 (−27.7%). 39 of 55 full years ended higher than they began.
Johnson & Johnson return by calendar year
Buy and hold, total return, from daily closes of our own data, to Nov 2026. Past returns do not guarantee future results.
Growth of 100 since 1970
buy & hold · dividends reinvested · to 19 Nov 2026Price history of JNJ, adjusted for share splits and with dividends reinvested, in US dollars. Weekly points in the charts; the figures above are from daily closes.
Johnson & Johnson against the S&P 500, Jan 1993 to Nov 2026
Over these 34 years Johnson & Johnson returned 12.6% a year and the S&P 500 10.6% a year, both with dividends reinvested. The single share earned more, and the worst fall of Johnson & Johnson on the way was shallower: −35.9% against −55.2%.
| Return a year | $10,000 became | Worst fall | |
|---|---|---|---|
| Johnson & Johnson JNJ | 12.6% | $548,000 | −35.9% |
| S&P 500 SPY | 10.6% | $298,000 | −55.2% |
The comparison starts in Jan 1993, the first month of our S&P 500 data. A past lead says nothing about the years ahead.
What drives Johnson & Johnson
New medicines and the expiry of patents on old ones, demand for surgery and medical devices, rules on drug prices, and the cost of lawsuits.
What can go wrong with a single share
It is one of the steadier large companies, with a long record of rising dividends, but patent expiries and legal cases can weigh on it for years. Steady does not mean it cannot fall: see the worst fall below.
One share or the whole index?
Whoever holds an S&P 500 fund already owns Johnson & Johnson: about $100 of every $10,000, next to 502 other stocks. A single company can do far better than the index for years and far worse for years, and nobody knows in advance which. That is the reason our systematic strategies follow whole markets and not single shares: the S&P 500, the Nasdaq-100 and 28 others, each reviewed once a month.
We have no strategy, no signal and no opinion on Johnson & Johnson shares. This page shows the public record so you can compare it with the index.
Questions about Johnson & Johnson shares
How much would $10,000 invested in Johnson & Johnson be worth today?
$10,000 put into Johnson & Johnson (JNJ) in Jan 1970 and left alone, with dividends reinvested, was worth about $7,581,000 in Nov 2026. That is 12.4% a year over 57 years, before taxes and costs.
What was the worst fall of Johnson & Johnson shares?
The deepest fall since 1970 was 50.7%, from the high in Nov 1972 to the low in Apr 1977. The shares were back at their old high in May 1981.
Has Johnson & Johnson done better than the S&P 500?
From Jan 1993 to Nov 2026 Johnson & Johnson returned 12.6% a year with a worst fall of 35.9%. The S&P 500 returned 10.6% a year over the same time with a worst fall of 55.2%. Both with dividends reinvested. A past lead says nothing about the years ahead.
How big is Johnson & Johnson in the S&P 500?
Johnson & Johnson made up 1.04% of the S&P 500 on 19 Nov 2026, which made it number 17 of 503 stocks by weight. Of every $10,000 held in an S&P 500 fund, about $100 was Johnson & Johnson.
Does InvestWealth have a strategy for Johnson & Johnson shares?
No. Our systematic strategies follow whole markets, such as the S&P 500 that Johnson & Johnson is part of, not single shares. This page shows the public price history of Johnson & Johnson so that it can be compared with the index. It is not a recommendation to buy or sell.
Other companies
All 10 companies → · All 30 markets →
Educational research, not investment advice and not a recommendation to buy or sell any share. Past returns do not guarantee future results. Disclaimer.
Get the month-end letter
- 30 markets after every month-end: what rose, what fell, and where each stands this year.
- The main asset classes in one table, from stocks and bonds to gold and Bitcoin.